Immunotherapy of cancer with dendritic-cell-based vaccines

Cancer Immunology Immunotherapy

Volumn 46, Issue 2, 1998, Pages 82-87

  Gilboa, Eli ^a   Nair, Smita K ^a   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dendritic cells; Immunotherapy; Tumor antigens; Tumor mRNA; Vaccines

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE EXPRESSION; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNIZATION; NEOPLASMS; PEPTIDES; POLYNUCLEOTIDES; RNA, NEOPLASM;

EID: 0031978249     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050465     Document Type: Conference Paper

References (37)

1. Anichini A, Mortarini R, Maccalli C, Squarcina P, Fleischhauer K, Mascheroni L, Parmiani G (1996) Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2.1-restricted immune repertoire to melanoma. J Immunol 156:208-217
2. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E (1994) The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 152:2324-2332
3. Boczkowski D, Nair SK, Snyder D, Gilboa E (1996) Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 184:465-472
4. Boon T, Bruggen P van der (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725-729
5. + T cells. J Exp Med 184:863-871
6. Dranoff G, Mulligan RC (1995) Gene transfer as cancer therapy. Adv Immunol 58:417-454
7. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor responses. Cell 60:397-403
8. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji B, Gilboa E (1990) Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217-1224
9. Gilboa E, Lyerly HK (1994) Specific active immunotherapy of cancer using genetically modified tumor vaccines. Biologic therapy of cancer updates. Lippincott, Philadelphia, 1-16
10. Girolomoni G, Ricciardi-Castagnoli P (1997) Dendritic cells hold promise for immunotherapy. Immunol Today 18:102-104
11. Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281-355
12. Herrath MG van, Yokoyama M, Dockter J, Oldstone MBA, Whitlon JL (1996) CD4-Deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol 70:1072-1079
13. Houghton AN (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med 180:1-4
14. Hu J, Kindsvogel W, Busby S, Bailey MC, Shi Y-Y, Greenberg PD (1993) An evaluation of the potential to use tumor-associated antigens at targets for antitumor T cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J Exp Med 177:1681-1690
15. Huang AYC, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H (1994) Role of bone marrow-derived cells in presenting MHC Class 1-restricted tumor antigens. Science 264:961-965
16. Huang AYC, Bruce AT, Pardoll DM, Levitsky HI (1996) Does B7-1 Expression confer Antigen-presenting Cell Capacity to tumors in vivo? J Exp Med 183:769-776
17. Ikeda H, Lethe B, Lehmann F, Van Baren N, Baurain JE, De Smet C, Chambost H, Vitale M, Moretta A, Boon T, Coulie PG (1997) Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 6:199-208
18. + T cells. Journal of Experimental Medicine 185:2133-2141
19. + cytolytic T lymphocytes. J Exp Med 183:791-800
20. Keene J, Forman J (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 155:768-782
21. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Medi 184:1953-1962
22. Matzinger P (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12:991-1045
23. Melero I, Singhal MC, McGowan P, Haugen HS, Blake J, Hellstrom KE, Yang G. Clegg CH, Chen L (1997) Immunological ignorance of an E7-encoded cytolytic T-lymphocyte epitope in transgenic mice expressing the E7 and E6 oncogenes of human papillomavirus type 16. J Virol 71:3998-4004
24. Nair S, Boczkowski D, Snyder D, Gilboa E (1997) Antigen presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur J Immunol 27:589-597
25. Nair S, Snyder D, Rouse BT, Gilboa E (1997) Regression of tumors in mice vaccinated with professional antigen presenting cells pulsed with tumor extracts. Cancer 70:706-715
26. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, Malissen B, Zinkernagel RM, Hengartner H (1991) Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305-317
27. Oldstone MBA, Nerenberg M, Southern P, Price J, Lewicki H (1991) Virus infection triggers insulin-dependent diabetes melitus in a transgenic model: role of anti-self (virus) immune responses. Cell 65:319-331
28. Parmiani G (1993) Tumor immunity as auto immunity: tumor antigens include normal self-proteins which stimulate anergic peripheral T cells. Immunol Today 14:536-538
29. Porgador A, Feldman M, Eisenbach L (1989) H-2Kb transfection of B16 melanoma cells results in reduced tumorigenicity and metastatic competence. Journal of Immunogenet 16:291-303
30. Reeves ME, Royal RE, Lam JS, Rosenberg SA, Hwu P (1996) Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 56:5672-5677
31. Rock KL, Clark K (1996) Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 156:3721-3726
32. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch P, Steinman R, Schuler G (1994) Proliferating dendritic cell progenitors in human blood. J Exp Med 180:83-93
33. Sauzet J-P, Gras-Masse H, Guillet J, Gomard E (1996)Influence of strong CD4 epitope on long-term virus-especific cytotoxic T cell responses induced in vivo with peptides. Int Immunol 8:457-465
34. Steinman RM (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9:271-296
35. Van Pel A, Boon T (1982) Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 79:4718-4722
36. Vierboom MPM, Nijman HW, Offringa R, Voorl EIH van der, Hall T van, Broek L van den, Fleuren GJ, Kenemans P, Kast WM, Melief JM (1997) Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 186:695-704
37. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ (1996) Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells. B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 183:87-97